Table 3

Frequency of adverse events by treatment group (intention to treat population)

Placebo (n=48)0.1% GTN (n=49)0.2% GTN (n=47)0.4% GTN (n=37)All patients (n=181)
χ2 test for trend, glyceryl trinitrate (GTN) versus placebo (χ2=50.5, p<0.0001).
Adverse event
    Headache (n (%))6 (12.5%)9 (18.3%)17 (36.1%)25 (67.5%)57 (31.5%)
    Severe headache (n (%))2 (4.2%)1 (2.0%) 3 (6.3%) 9 (24.3%)14 (7.7%)